AR110055A2 - Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos - Google Patents

Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos

Info

Publication number
AR110055A2
AR110055A2 ARP170103140A ARP170103140A AR110055A2 AR 110055 A2 AR110055 A2 AR 110055A2 AR P170103140 A ARP170103140 A AR P170103140A AR P170103140 A ARP170103140 A AR P170103140A AR 110055 A2 AR110055 A2 AR 110055A2
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
heteroalkyl
arylalkyl
acyl
Prior art date
Application number
ARP170103140A
Other languages
English (en)
Original Assignee
Senomyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senomyx Inc filed Critical Senomyx Inc
Publication of AR110055A2 publication Critical patent/AR110055A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Reivindicación 1: Un compuesto, excluyendo su uso terapéutico, que tiene la fórmula estructural (1), o un tautómero o sal del mismo, en donde: A es alquilo, alquilo sustituido, halo, -CN, -NO₂, -OR⁹, SR⁹, -NHOR⁹, -NR⁹R¹⁰ o -NOR⁹; B es -N- o -C(R¹²)-; (D)ₙ-G es un resto de fórmula (2) ó (3); E es -NR¹⁷, -N- o -C(R¹⁸)-; H es -C(R³⁵)- o -N-; I es -C(R³⁶) o -N-; J es -C(R³⁷)- o -N-; K es -C(R³⁸)- o -N-; R⁹, R¹⁰, R¹³, R¹⁴ y R¹⁸ son independientemente hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo o heteroarilalquilo sustituido; o alternativamente, R⁹ y R¹⁰ o R¹³ y R¹⁴, junto con los átomos a los cuales están unidos, forman un anillo cicloheteroalquilo o cicloheteroalquilo sustituido; R¹² es hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -NR¹³R¹⁴, CN, -OR¹³, -CO₂R¹³ o -CONR¹³R¹⁴; R¹⁷ es hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo o heteroarilalquilo sustituido; R³⁵ es hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, halo, cicloalquenilo, cicloalquenilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -CN, -NO₂, -OR³⁹, -NR³⁹R⁴⁰, -CONR³⁹R⁴⁰ o -CO₂R³⁹; R³⁶ es hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, halo, cicloalquenilo, cicloalquenilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -CN, -NO₂, -OR⁴¹, NR⁴¹R⁴², -CONR⁴¹R⁴² o -CO₂R⁴¹; R³⁷ es hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, halo, cicloalquenilo, cicloalquenilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -CN, -NO₂, -OR⁴³, -NR⁴³R⁴⁴, -CONR⁴³R⁴⁴ o -CO₂R⁴³; R³⁸ es hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, halo, cicloalquenilo, cicloalquenilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -CN, -NO₂, -OR⁴⁵, -NR⁴⁵R⁴⁶, -CONR⁴⁵R⁴⁶, -COR⁴⁵ o -CO₂R⁴⁵; o alternativamente R³⁶ y R³⁷ o R³⁷ y R³⁸, tomados junto con el átomo al cual están unidos, forman un anillo cicloalquilo, cicloalquilo sustituido, cicloheteroalquilo, o cicloheteroalquilo sustituido; R³⁹, R⁴⁰, R⁴¹, R⁴², R⁴³, R⁴⁴, R⁴⁵ y R⁴⁶ son independientemente hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo o heteroarilalquilo sustituido, o alternativamente R³⁹ y R⁴⁰, R⁴¹ y R⁴², R⁴³ y R⁴⁴ o R⁴⁵ y R⁴⁶, junto con los átomos a los cuales están unidos, forman un anillo cicloheteroalquilo o cicloheteroalquilo sustituido; con la condición de que, como máximo, dos de H, I, J y K sean -N-.
ARP170103140A 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos AR110055A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/760,592 US9603848B2 (en) 2007-06-08 2007-06-08 Modulation of chemosensory receptors and ligands associated therewith

Publications (1)

Publication Number Publication Date
AR110055A2 true AR110055A2 (es) 2019-02-20

Family

ID=40096447

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP170103139A AR110054A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103140A AR110055A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103138A AR110053A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103141A AR110056A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170103139A AR110054A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP170103138A AR110053A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103141A AR110056A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos

Country Status (2)

Country Link
US (1) US9603848B2 (es)
AR (4) AR110054A2 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US7585868B2 (en) 2006-04-04 2009-09-08 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
ES2647947T3 (es) 2008-07-31 2017-12-27 Senomyx, Inc. Procesos y productos intermedios para la preparación de potenciadores del sabor dulce
EP2328426B1 (en) 2008-07-31 2014-10-01 Senomyx, Inc. Compositions comrpising sweetness enhancers and methods of making them
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110224250A1 (en) * 2008-10-09 2011-09-15 Yasushi Kohno Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
EP2352505B1 (en) 2008-11-04 2016-07-06 University Of Kentucky Research Foundation D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
WO2010103306A1 (en) * 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
AU2010239311B2 (en) 2009-04-20 2014-05-22 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
NZ597050A (en) 2009-06-29 2014-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
LT3575288T (lt) 2009-09-03 2021-12-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011056566A2 (en) * 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
US8680108B2 (en) * 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
PE20130211A1 (es) 2010-04-02 2013-03-22 Senomyx Inc Modificador del sabor dulce
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
CN106107406B (zh) 2010-08-12 2020-06-09 弗门尼舍公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
EP2630491A4 (en) 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
US20120177730A1 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20140050711A (ko) * 2011-08-12 2014-04-29 세노믹스, 인코포레이티드 단맛 향미 변형제
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
BR122019020716B1 (pt) 2011-09-02 2021-02-17 Incyte Holdings Corporation heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP3593648B1 (en) 2012-08-06 2021-07-14 Firmenich Incorporated Sweet flavor modifier
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
TWI719464B (zh) 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
CA2926950C (en) 2013-10-10 2022-10-11 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
DK3674302T3 (da) 2014-04-23 2023-04-03 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN106456592B (zh) 2014-06-27 2019-06-18 味之素株式会社 甜味受体拮抗剂
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US11339128B2 (en) 2014-11-07 2022-05-24 Firmenich Incorporated Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers
MD3262046T2 (ro) 2015-02-27 2021-03-31 Incyte Corp Săruri de inhibitori ai PI3K și procedee pentru prepararea lor
MD20170081A2 (ro) 2015-03-04 2018-03-31 Gilead Sciences, Inc. Compuşi 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
CN105232565B (zh) * 2015-08-13 2017-12-08 北京农学院 罗汉果皂苷或其药学上可接受的盐在制备肿瘤放射增敏剂中的应用
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
DK3322695T3 (da) 2016-09-21 2020-09-28 Celanese Int Corp Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
LT3317260T (lt) 2016-09-21 2020-01-27 Celanese International Corporation Acesulfamo kalio kompozicijos ir jų gamybos būdai
LT3319949T (lt) 2016-09-21 2020-11-10 Celanese International Corporation Kalio acesulfamo kompozicijos ir jų gamybos būdas
JP7169977B2 (ja) 2016-09-21 2022-11-11 セラニーズ・インターナショナル・コーポレーション アセスルファムカリウム組成物及びその製造方法
UY37764A (es) 2017-06-13 2019-01-02 Glaxosmithkline Ip Dev Ltd Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
MX2021001193A (es) 2018-08-07 2021-04-28 Firmenich Incorporated 2,2-dioxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-sustituidos y formulaciones y usos de los mismos.
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN115279771A (zh) 2020-01-15 2022-11-01 缆图药品公司 Map4k1抑制剂
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4258897A1 (en) 2021-01-15 2023-10-18 Firmenich Incorporated Sweetener compositions comprising mogrosides and uses thereof
US20240090547A1 (en) 2021-01-15 2024-03-21 Firmenich Incorporated Sweetener compositions comprising mogrosides and uses thereof
CN116963609A (zh) 2021-01-15 2023-10-27 弗门尼舍公司 包含罗汉果苷的甜味剂组合物及其用途
WO2023172415A1 (en) 2022-03-07 2023-09-14 Firmenich Incorporated Sweetener compositions
WO2023169995A1 (en) 2022-03-10 2023-09-14 Firmenich Sa Sweetener compositions
WO2023198436A2 (en) 2022-04-11 2023-10-19 Firmenich Sa Sweetener compositions
WO2024085749A1 (en) 2022-10-20 2024-04-25 Technische Universiteit Eindhoven A non-aqueous redox flow battery

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB951651A (en) 1960-02-17 1964-03-11 Shell Res Ltd Substituted benzonitriles, their preparation and compositions containing them
US3278532A (en) 1964-07-06 1966-10-11 Sandoz Ag Dioxybenzothiadiazines
US3857972A (en) * 1971-03-10 1974-12-31 Int Flavors & Fragrances Inc Flavoring with an oxocyclic pyrimidine
US3843804A (en) * 1971-03-10 1974-10-22 Int Flavors & Fragrances Inc Novel flavoring compositions and processes
LU64388A1 (es) 1971-12-02 1973-07-16
FI54312C (fi) 1972-05-09 1978-11-10 Sumitomo Chemical Co Foerfarande foer framstaellning av tieno-(2,3-d)pyrimidinderivat med avsoendring av urinsyra i urin utoekande
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3960860A (en) * 1973-01-08 1976-06-01 International Flavors & Fragrances Inc. 2-Methyl-5,7-dihydrothieno-[3,4d]-pyrimidine
US3966965A (en) 1973-03-23 1976-06-29 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4036837A (en) 1973-03-23 1977-07-19 American Home Products Corporation 2 Alkoxyoxamoyl-pyrazines
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3960783A (en) * 1974-04-01 1976-06-01 Ciba-Geigy Corporation Novel polymers from s-triazine cyanamide compounds
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4137325A (en) 1977-03-17 1979-01-30 American Home Products Corporation Antisecretory oxamic acid esters
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
ES472163A1 (es) 1978-07-28 1979-03-16 Consejo Superior Investigacion Ÿun nuevo procedimiento para la obtencion de 5,5-dioxido de 7-amino-2h-4h-vic-triazolo (4,5-c) (1,2,6) tiadiazinaÿ
IE51802B1 (en) * 1979-12-03 1987-04-01 Fujisawa Pharmaceutical Co Quinazoline derivatives,processes for their preparation and pharmaceutical compositions containing them
JPS5951290A (ja) 1982-09-14 1984-03-24 Dai Ichi Seiyaku Co Ltd ベンゾチエノイミダゾピリミジンジオン化合物
ES8507558A1 (es) 1984-03-30 1985-09-01 Consejo Superior Investigacion Procedimiento para la preparacion de aminociclotiadiazinas
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4672116A (en) 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
JPS6387959A (ja) 1986-10-01 1988-04-19 Sanyo Kokusaku Pulp Co Ltd ステビア甘味料の呈味性改善法
US4960870A (en) 1987-02-11 1990-10-02 Ciba-Geigy Corporation Heavy metal complex azo dyes containing a benzothiophene-1,1-dioxide, 2,1-benzothiazine-2,2-dioxide, 1,4-benzothiazine-1,1-dioxide or thienopyridine-1,1-dioxide coupling component
WO1989000563A1 (en) 1987-07-17 1989-01-26 The Nutrasweet Company High potency sweetening agents
US5380541A (en) * 1987-08-07 1995-01-10 Tate & Lyle Public Limited Company Sucralose compositions
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JPH02238856A (ja) 1989-03-14 1990-09-21 Mitajiri Kagaku Kogyo Kk ミラクリンを有効成分とする矯味・調味料及びこれを含有する飲食品
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5504095A (en) * 1990-09-19 1996-04-02 Pfizer Inc. Aminobenzosultam derivatives as lipoxygenase inhibitors
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
IL102764A0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9127188D0 (en) 1991-12-21 1992-02-19 Smithkline Beecham Plc Novel compounds
KR970010069B1 (ko) 1992-08-24 1997-06-20 주식회사 럭키 신규 세팔로스포린계 항생제 및 이의 제조방법
WO1996028205A1 (en) * 1995-03-14 1996-09-19 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
ZA962077B (en) * 1995-03-14 1997-03-26 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
WO1998027831A2 (de) 1996-12-20 1998-07-02 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Verfahren zur verstärkung der süsskraft und zur geschmacksverbesserung einer mischung hochintensiver süssstoffe
KR100220953B1 (ko) 1996-12-31 1999-10-01 김영환 아미드 또는 이미드를 도입한 ArF 감광막 수지
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US5990117A (en) 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
WO1999061428A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
US6169118B1 (en) 1998-11-12 2001-01-02 Block Drug Company, Inc. Flavor blend for masking unpleasant taste of zinc compounds
JP2003500397A (ja) 1999-05-19 2003-01-07 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｍｒｓ阻害剤としての２−ｎｈ−ピリドンおよびピリミドン
GB9915995D0 (en) 1999-07-09 1999-09-08 Ahmed S Non-steroidal sulphamate compounds for use as oestrone sulphatase inhibitors
JP3523166B2 (ja) 1999-09-02 2004-04-26 高砂香料工業株式会社 食品香料劣化防止剤、食品香料劣化防止方法およびその食品香料劣化防止剤を含有する食品
TW201006846A (en) * 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
MXPA02009843A (es) * 2000-04-07 2004-09-06 Senomyx Inc Receptores t2r del sabor y genes que codifican para los mismos.
TW201022287A (en) * 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
JP4300457B2 (ja) 2001-03-02 2009-07-22 住友化学株式会社 キノリン−３−カルボン酸化合物の製造方法
US7368285B2 (en) * 2001-03-07 2008-05-06 Senomyx, Inc. Heteromeric umami T1R1/T1R3 taste receptors and isolated cells that express same
EP2003451B1 (en) 2001-06-26 2012-05-30 Senomyx, Inc. T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds
CA2452716C (en) 2001-07-03 2012-06-26 The Regents Of The University Of California Mammalian sweet and amino acid heterodimeric taste receptors
US20060134693A1 (en) 2001-07-06 2006-06-22 Guy Servant Olfactory cyclic nucleotide-gated channel cell-based assays to identify T1R and T2R taste modulators
DE60208908T8 (de) 2001-07-19 2008-04-10 San-Ei Gen F.F.I., Inc., Toyonaka Geschmacksverbessernde zusammensetzungen und ihre anwendung
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
EP1458718B1 (en) 2001-12-14 2006-10-25 Merck Frosst Canada Ltd. Quinolinones as prostaglandin receptor ligands
WO2003055866A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US20040127435A1 (en) * 2002-08-02 2004-07-01 Regents Of The University Of California Uses for inhibitors of inosine monophosphate dehydrogenase
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
DE10324548A1 (de) 2003-05-28 2004-12-16 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Diätisches Lebensmittel bei einer gewichtskontrollierenden bzw. gewichtsreduzierenden Ernährung
CA2900181C (en) 2003-08-06 2019-01-29 Catherine Tachdjian Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
WO2005016889A1 (en) 2003-08-08 2005-02-24 Virginia Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties
WO2005087020A1 (en) 2004-03-05 2005-09-22 Richmond Chemical Corporation High-intensity sweetener-polyol compositions
EP1753864A2 (en) 2004-04-14 2007-02-21 Monell Chemical Senses Center Taste receptors of the t1r family from domestic dog
EP3121176A1 (en) 2004-06-08 2017-01-25 Families of Spinal Muscular Atrophy 2,4-diaminoquinazolines for the treatment of spinal muscular atrophy
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
RU2392834C2 (ru) 2004-10-15 2010-06-27 Адзиномото Ко., Инк. Композиция подсластителя
US20080261823A1 (en) 2004-12-10 2008-10-23 Yitzhak Tor Fluorescent Nucleoside Analogs That Mimic Naturally Occurring Nucleosides
ES2324231T3 (es) * 2004-12-17 2009-08-03 F. Hoffmann-La Roche Ag Derivados de tieno-piridina como intensificadores alostericos de gaba-b.
WO2006084184A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Molecules comprising linked organic moieties as flavor modifiers for comestible compositions
RU2410383C2 (ru) 2005-02-04 2011-01-27 Синомикс, Инк. Соединения, включающие связанные гетероарильные фрагменты, и их применение в качестве новых модификаторов вкусо-аромата умами, тастантов (стимуляторов сенсорных клеток вкусовых сосочков языка) и усилителей вкуса в пищевых композициях
WO2006113422A2 (en) 2005-04-13 2006-10-26 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Human sweet and umami taste receptor variants
EP1874753A2 (en) 2005-04-14 2008-01-09 Smithkline Beecham Corporation Compounds, compositions and methods
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
JP2007007591A (ja) 2005-07-01 2007-01-18 Mikuni Corp 電解水及びその製造方法
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors
JP5342878B2 (ja) 2005-10-20 2013-11-13 セノミクス・インコーポレーテッド キメラヒト甘味‐旨味および旨味‐甘味味覚受容体
US8506956B2 (en) 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
CN101341133A (zh) 2005-12-22 2009-01-07 阿斯利康(瑞典)有限公司 喹唑啉衍生物，其制备方法及其作为抗癌药的用途
EP2035405A1 (de) 2006-07-05 2009-03-18 Merck Patent GmbH Sulfamat-benzothiophen-derivate
US7674831B2 (en) 2006-08-22 2010-03-09 Redpoint Bio Corporation Heterocyclic compounds as sweetener enhancers
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) * 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009006722A1 (en) 2007-07-12 2009-01-15 Mehrzad Gomari Paper-free local flyer advertising (a technology method of localized internet advertising)
EP2328426B1 (en) 2008-07-31 2014-10-01 Senomyx, Inc. Compositions comrpising sweetness enhancers and methods of making them
ES2647947T3 (es) * 2008-07-31 2017-12-27 Senomyx, Inc. Procesos y productos intermedios para la preparación de potenciadores del sabor dulce
PE20130211A1 (es) 2010-04-02 2013-03-22 Senomyx Inc Modificador del sabor dulce
RU2527540C1 (ru) 2010-06-29 2014-09-10 Фирмениш Са Система доставки активного ингредиента
CN106107406B (zh) * 2010-08-12 2020-06-09 弗门尼舍公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
AU2011317143A1 (en) 2010-10-19 2013-05-30 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP3593648B1 (en) 2012-08-06 2021-07-14 Firmenich Incorporated Sweet flavor modifier
JO3155B1 (ar) * 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة

Also Published As

Publication number Publication date
AR110054A2 (es) 2019-02-20
US20080306093A1 (en) 2008-12-11
US9603848B2 (en) 2017-03-28
AR110053A2 (es) 2019-02-20
AR110056A2 (es) 2019-02-20

Similar Documents

Publication Publication Date Title
AR110055A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
EA201891841A1 (ru) 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
AR098912A1 (es) Inhibidores de syk
AR089807A1 (es) Compuestos de imidazopirrolidinona
DOP2015000239A (es) Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores del bromodominio
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
MA39189A1 (fr) Dérivés de 1h-indazole et de 1h-indole antibactériens
AR095347A1 (es) Compuestos orgánicos
CO6561817A2 (es) Derivados de piridina di-sustituida como agentes anticancer
AR092838A1 (es) COMPUESTOS TIPO PIRROLO-PIRROLIDINONA COMO INHIBIDORES DE LA INTERACCION ENTRE p53 Y MDM2 Y/O MDM4
BRPI1011683B8 (pt) derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos
AR096837A1 (es) Heterociclos tricíclicos como inhibidores de proteínas bet
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
AR079250A1 (es) Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis.
AR106961A1 (es) Amidas de ácido malónico sustituidas como insecticida
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
CO6480974A2 (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb)
CY1117560T1 (el) Νεο υποκατασταθεν παραγωγο ισοκινολινης
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
AR099690A1 (es) Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina
MA20150280A2 (fr) Dérivés d'aryléthynyle
BR112014004267A2 (pt) derivado de ácido pirrolidina-3-ilacético

Legal Events

Date Code Title Description
FB Suspension of granting procedure